Clinical trials: Progression of Non-small Cell Lung Cancer
NSCLC
Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients
Between 10% and 25% of newly diagnosed stage IIIB/stage IV patients currently receive single agent chemotherapy regimens. A significant proportion of these patients will be elderly (70 years of age) and many oncologists would…
- Trial name
- NCT00754364
- Testing
- Pemetrexed/Carboplatin, Gemcitabine
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Armando Santoro, MD
Lung Cancer, Psychological Stress
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer.
- Conditions
- Lung Cancer, Psychological Stress, Immune Checkpoint Inhibitors, Cancer, Treatment-Related
- Trial name
- NCT05477979
- Testing
- Exposure: psychological stress status
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Second Xiangya Hospital of Central South University
Non-Small Cell Lung Cancer
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer…
- Trial name
- ARCHER 1009 (NCT01360554)
- Testing
- Dacomitinib (PF-00299804), Active Comparator (erlotinib)
- Where
- 224 sites in United States, Austria and 21 more
- Volunteers
- 878 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer NSCLC
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC…
- Trial name
- POSEIDON (NCT03164616)
- Testing
- Durvalumab, Tremelimumab, Abraxane + carboplatin
- Where
- 175 sites in United States, Brazil and 17 more
- Volunteers
- 1,186 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
The Continuation of Erlotinib
Newly developed or progressive brain metastasis during erlotinib treatment is considered progressive disease requiring change of treatment regimens despite no progression in extracranial lesions.
- Trial name
- NCT01130779
- Testing
- Erlotinib (TARCEVA®)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00354549
- Testing
- bevacizumab + erlotinib hydrochloride, gemcitabine hydrochloride + cisplatin or carboplatin
- Where
- 2 sites in Switzerland
- Volunteers
- 104 people
- Sponsor
- Swiss Cancer Institute
Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
Patients with metastatic non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) expression below 50% are commonly treated with different chemo-immunotherapy regimens in routine clinical practice.
- Trial name
- ALCG-01 (NCT07394062)
- Testing
- Pembrolizumab, Nivolumab, Ipilimumab (1mg/kg)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 400 people
- Sponsor
- Gazi University
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Non-Small-Cell Lung Carcinoma
Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
The purpose of this study is to establish the safest dose of the investigational medication Belinostat that can be administered with a standard of care chemotherapy regimen of bevacizumab, carboplatin, and paclitaxel.
- Trial name
- HCH003 (NCT01090830)
- Testing
- Belinostat, carboplatin, paclitaxel and bevacizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Holy Cross Hospital, Florida
Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab…
- Trial name
- NCT07155187
- Testing
- Telisotuzumab Adizutecan, Standard of Care, Osimertinib
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 490 people
- Sponsor
- AbbVie
Non Small Cell Lung Cancer, T790M
Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC
The single-arm phase II APOLLO study demonstrated favorable antitumor activity and an acceptable safety profile for aumolertinib in patients with EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer after…
- Conditions
- Non Small Cell Lung Cancer, T790M, EGFR Activating Mutation
- Trial name
- AUMO-RWE (NCT07838532)
- Testing
- Aumolertinib monotherapy （development code: HS-10296）
- Where
- China
- Volunteers
- 637 people
- Sponsor
- Xin Li
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
This phase II trial tests the safety and effectiveness of the combination of grid radiation therapy and standard of care (SOC) immunotherapy in treating patients with stage IV non-small lung cancer (NSCLC).
- Trial name
- NCT06660407
- Testing
- Biospecimen Collection, Computed Tomography, Immunotherapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
This open-label, single arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as first-line therapy in participants with stage IV or recurrent non-small cell lung cancer who harbour epidermal growth factor…
- Trial name
- NCT01310036
- Testing
- Erlotinib
- Where
- 22 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations
This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC…
- Trial name
- NCT03799094
- Testing
- Vitamin C, Tyrosine kinase inhibitor
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Clifford Hospital, Guangzhou, China
Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC)…
- Trial name
- NCT07361705
- Testing
- Zorifertinib and Osimertinib Combination Therapy
- Where
- 5 sites in China
- Volunteers
- 42 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
This is a randomized, open-label, phase 3 study evaluating nogapendekin alfa inbakicept (NAI) plus chemoimmunotherapy containing pembrolizumab and platinum-based chemotherapy versus chemoimmunotherapy alone as first-line…
- Trial name
- NCT07524257
- Testing
- Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab, Cisplatin or Carboplatin
- Sponsor
- ImmunityBio, Inc.
Lung Cancer, Lymphoma
Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01567722
- Testing
- DNA analysis, RNA analysis, gene expression analysis
- Where
- 14 sites in United States
- Volunteers
- 114 people
- Sponsor
- AIDS Malignancy Consortium
EGFR Positive Non-small Cell Lung Cancer
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC
Tyrosine kinase inhibitors (TKI) have greatly improved prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), with tumor responses in the majority of cases and a median overall survival…
- Trial name
- NCT04105153
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Thoraxklinik-Heidelberg gGmbH
Small-cell Lung Cancer
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease…
- Trial name
- NCT06789796
- Testing
- Iparomlimab and Tuvonralimab (QL1706), QL1604
- Volunteers
- 636 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability…
- Conditions
- Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
- Trial name
- NCT00054795
- Testing
- Motexafin Gadolinium
- Where
- 92 sites in United States, Australia and 6 more
- Volunteers
- 550 people
- Sponsor
- Pharmacyclics LLC.